Concert Pharmaceuticals Releases Information on Upcoming CTP-543 Phase 3 Trials
Leading off of the Phase 2 CTP-543 trials, Chief Development Officer of Concert Pharmaceuticals, Dr. James V. Cassella states: “The planned initiation
Phase 2 of CTP-543 Trial Brings Positive News
Positive results have been reported following the completion of the CTP-543 Phase 2 trial. More than 75% of patients receiving two daily
Clinical Trials Now Recruiting in Ontario & Quebec
Clinical trials are being conducted by Concert Pharmaceuticals Inc., to investigate a new treatment called CTP‑543 in adults, age 18 to 65